Active	Status	Sponsor type	Region	Phase	Filter
5 Active 6 Inactive 11 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

5 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Hochhaus, Andreas
DasaHIT, NCT02890784 / 2015-003502-16: Dasatinib Holiday for Improved Tolerability	Completed	3	291	Europe	dasatinib (SPRYCEL®)	University of Jena	Myeloid Leukemia, Chronic	03/23	03/23
ELVN-001-101, NCT05304377: A Phase 1a/1b Study of ELVN-001 for the Treatment Chronic Myeloid Leukemia	Recruiting	1	180	Europe, Canada, US, RoW	ELVN-001	Enliven Therapeutics	Chronic Myeloid Leukemia, Chronic Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive, Cml	12/26	12/26
Ponderosa, NCT03933852: Observational Study on Chronic Myeloid Leukemia Patients in Any Phase Treated With Ponatinib (Iclusig®) at Any Dose	Active, not recruiting	N/A	100	Europe		University of Jena	Chronic Myeloid Leukemia, Chronic Phase	06/24	12/24
NCT03188874: Clinical AML Registry and Biomaterial Database of the Study Alliance Leukemia (SAL)	Recruiting	N/A	15000	Europe		Technische Universität Dresden	Acute Myeloid Leukemia (AML)	09/30	09/30
NCT03125707: German MPN-Registry for BCR-ABL 1-Negative Myeloid Neoplasms (Study Group Ulm)	Recruiting	N/A	2172	Europe	Registry study	University of Ulm	BCR-ABL1-Negative Myeloid Neoplasms	09/45	09/45